Novavax Inc vs CYATY
A head-to-head of Novavax Inc (NVAX) and CYATY (CYATY) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | NVAX | CYATY |
|---|---|---|
| Market Cap | $1.30B | $372.43B |
| P/E (TTM) | 3.13 | 31.75 |
| Forward P/E | 2.58 | 29.07 |
| P/S | 1.16 | 0.80 |
| P/B | 33.20 | 6.98 |
| EV/EBITDA | 1.71 | 16.60 |
| Dividend Yield | — | 0.00% |
| Profit Margin | 39.19% | 16.87% |
| Gross Margin | 93.67% | 25.62% |
| Operating Margin | 50.14% | 15.29% |
| Revenue Growth (YoY) | +66.61% | +52.45% |
| FCF Yield | -19.24% | 23.93% |
| Debt / Equity | — | 27.90 |
| Current Ratio | 2.13 | 1.60 |
Which is better: Novavax Inc or CYATY?
- ✓Larger by market cap: CYATY
- ✓Cheaper valuation (lower P/E): Novavax Inc
- ✓More profitable (net margin): Novavax Inc
- ✓Faster revenue growth: Novavax Inc
- ✓Higher free-cash-flow yield: CYATY
Across 11 available metrics, Novavax Inc leads 8–3.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Novavax Inc with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.